BioSpectrum
the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

MediCircle Health launches SpectraLIT in India market

12 July 2021 | News

The portable spectrophotometry-based testing platform is powered by machine learning and artificial intelligence to detect COVID-19 by using an individualâ??s nasal or mouthwash sample



MediCircle Health, an AI-powered diagnostics company, is introducing the SpectraLIT - Spectral Instant Test in India. SpectraLIT is a portable spectrophotometry-based testing platform that is powered by machine learning and artificial

intelligence to detect COVID-19 by using an individual's nasal or mouthwash sample. This eliminates the need for complex lab equipment and chemicals by providing immediate results using the spectral signature of the virus. The AI algorithm enables SpectraLIT to distinguish between an infected person and a healthy person. Additionally, the algorithm can be adjusted to detect different variants of the SARS-CoV-2 coronavirus.

SpectraLIT is developed by Newsight Imaging which specialises in developing advanced machine vision chip sensors in collaboration with the reputed Sheba Medical Center's ARC Innovation Center in Israel. The technology is licensed to Hong Kong-based AI Innobio for the Asia-Pacific region. MediCircle Health has an exclusive tie-up with AIInnoBio to launch the test in India.

Eventually, SpectraLIT will be able to test for diseases other than COVID-19. The platform will grow and innovations will allow it to detect other infectious diseases such as influenza, tuberculosis, malaria, dengue, and UTIs, as well as non-communicable diseases such as sickle cell disease.

SpectraLIT has received the European Union CE-IVD mark of authorization for use in the diagnosis of COVID-19, which is recognised and accepted in India by ICMR. It has been launched in seven countries and has been approved by ICTS, the European airport security giant to offer a quick COVID-19 screening process at European airports. It has also been tested in 36 hospitals across North and Latin America, Asia Pacific, Europe, and the Middle East. SpectraLIT is currently undergoing FDA approvals in the US.